Production and Characterization of a Human Monoclonal Antibody, Reactive with a Conserved Epitope on gp41 of Human Immunodeficiency Virus Type I

1990 ◽  
Vol 6 (3) ◽  
pp. 381-392 ◽  
Author(s):  
VERA J.P. TEEUWSEN ◽  
KEES H.J. SIEBELINK ◽  
SYLVIA CRUSH-STANTON ◽  
BONNIE SWERDLOW ◽  
JOHN J. SCHALKEN ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Human Monoclonal Antibody ◽  
Type I ◽  
Immunodeficiency Virus ◽  
Conserved Epitope

Crystallization of the Fab from a human monoclonal antibody against gp 41 of human immunodeficiency virus type I

1990 ◽  
Vol 216 (3) ◽  
pp. 511-512 ◽  
Author(s):  
Elena Casale ◽  
Elisabeth Wenisch ◽  
Xiao-min He ◽  
Pier Giorgio Righetti ◽  
Robert S. Snyder ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Human Monoclonal Antibody ◽  
Type I ◽  
Immunodeficiency Virus

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1*

1996 ◽  
Vol 59 (6) ◽  
pp. 662-667 ◽  
Author(s):  
Erika J. Wolfe ◽  
Lisa A. Cavacini ◽  
Matthew H. Samore ◽  
Marshall R. Posner ◽  
Carolyn Kozial ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Human Monoclonal Antibody ◽  
Immunodeficiency Virus

scholarly journals Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12

2001 ◽  
Vol 75 (14) ◽  
pp. 6692-6699 ◽  
Author(s):  
Michael B. Zwick ◽  
Lori L. C. Bonnycastle ◽  
Alfredo Menendez ◽  
Melita B. Irving ◽  
Carlos F. Barbas ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Binding Site ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Human Monoclonal Antibody ◽  
Recombinant Polypeptide ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT Human monoclonal antibody (MAb) b12 recognizes a conformational epitope that overlaps the CD-4-binding site of the human immunodeficiency virus type 1 (HIV-1) envelope. MAb b12 neutralizes a broad range of HIV-1 primary isolates and protects against primary virus challenge in animal models. We report here the discovery and characterization of B2.1, a peptide that binds specifically to MAb b12. B2.1 was selected from a phage-displayed peptide library by using immunoglobulin G1 b12 as the selecting agent. The peptide is a homodimer whose activity depends on an intact disulfide bridge joining its polypeptide chains. Competition studies with gp120 indicate that B2.1 occupies the b12 antigen-binding site. The affinity of b12 for B2.1 depends on the form in which the peptide is presented; b12 binds best to the homodimer as a recombinant polypeptide fused to the phage coat. Originally, b12 was isolated from a phage-displayed Fab library constructed from the bone marrow of an HIV-1-infected donor. The B2.1 peptide is highly specific for b12 since it selected only phage bearing b12 Fab from this large and diverse antibody library.

scholarly journals Two N-Linked Glycosylation Sites in the V2 and C2 Regions of Human Immunodeficiency Virus Type 1 CRF01_AE Envelope Glycoprotein gp120 Regulate Viral Neutralization Susceptibility to the Human Monoclonal Antibody Specific for the CD4 Binding Domain

2010 ◽  
Vol 84 (9) ◽  
pp. 4311-4320 ◽  
Author(s):  
Piraporn Utachee ◽  
Shota Nakamura ◽  
Panasda Isarangkura-na-ayuthaya ◽  
Kenzo Tokunaga ◽  
Pathom Sawanpanyalert ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Envelope Glycoprotein ◽  
Human Monoclonal Antibody ◽  
Binding Domain ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT A recombinant human monoclonal antibody, IgG1 b12 (b12), recognizes a conformational epitope on human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120 that overlaps the CD4 binding domain. Although b12 is able to broadly neutralize HIV-1 subtype B, C, and D viruses, many HIV-1 CRF01_AE viruses are resistant to b12-mediated neutralization. In this report, we examined the molecular mechanisms underlying the low neutralization susceptibility of CRF01_AE viruses to b12, using recently established CRF01_AE Env recombinant viruses. Our results showed that two potential N-linked glycosylation (PNLG) sites in the V2 and C2 regions of Env gp120 played an important role in regulating the susceptibility of CRF01_AE Env to b12. The locations of these PNLG sites correspond to amino acid positions 186 and 197 in HXB2 Env gp120; thus, they are designated N186 and N197 in this study. Removal of N186 significantly conferred the b12 susceptibility of 2 resistant CRF01_AE Env clones, 65CC4 and 107CC2, while the introduction of N186 reduced the b12 susceptibility of a susceptible CRF01_AE Env clone, 65CC1. In addition, removal of both N186 and N197 conferred the b12 susceptibility of 3 resistant CRF01_AE Env clones, 45PB1, 62PL1, and 101PL1, whereas the removal of either N186 or N197 was not sufficient to confer the b12 susceptibility of these CRF01_AE Env clones. Finally, removal of N197 conferred the b12 susceptibility of 2 resistant CRF01_AE Env clones lacking N186, 55PL1 and 102CC2. Taken together, we propose that two PNLG sites, N186 and N197, in Env gp120 are important determinants of the b12 resistance of CRF01_AE viruses.

Sign in / Sign up

Export Citation Format

Share Document